Browsing Tag
Vaximm AG
3 posts
OSR Holdings (NASDAQ: OSRH) explores royalty-driven licensing for Vaximm’s cancer therapy
Vaximm may license its oral cancer therapy VXM01 in a deal worth up to $815M. Find out how OSR Holdings plans to turn this into a royalty-driven biotech play.
Vaximm AG advances VXM01 strategy with BCM Europe term sheet offering US$20m upfront and US$815m upside
Learn how Vaximm AG’s new term sheet with BCM Europe sets the stage for a US$20M upfront license deal and up to US$815M in milestones.
Why OSR Holdings (NASDAQ: OSRH) chose its scientific founder to lead Vaximm’s next immunotherapy chapter
OSR Holdings appoints scientific founder Dr. Andreas Niethammer as CEO of Vaximm AG to lead next-gen cancer immunotherapy strategy. Read more.